Literature DB >> 8825919

Detection of germline mutations in the von Hippel-Lindau disease gene by the primer specified restriction map modification method.

T Kishida1, F Chen, M I Lerman, B Zbar.   

Abstract

Von Hippel-Lindau disease (VHL) is an inherited disorder characterised by a predisposition to develop tumours in the eyes, central nervous system, kidneys, and adrenal glands. Recently the VHL gene was cloned and shown to be mutated in 75% of US and Canadian VHL families. To develop simple, rapid methods for the detection of mutations found in large numbers of affected people, we designed based on the primer specified restriction site modification method. These tests have proved useful in identifying asymptomatic mutated VHL gene carriers who have the nt 505 T to C mutation or the nt 686 T to C mutation. Together with an MspI digestion test which can detect a mutation hot spot in codon 238, polymerase chain reaction/restriction endonuclease based tests can now detect VHL mutations in more than 50% of VHL type 2 families.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8825919      PMCID: PMC1051772          DOI: 10.1136/jmg.32.12.938

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  21 in total

1.  Modification of enzymatically amplified DNA for the detection of point mutations.

Authors:  A Haliassos; J C Chomel; L Tesson; M Baudis; J Kruh; J C Kaplan; A Kitzis
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

2.  Mapping of the von Hippel-Lindau disease locus to a small region of chromosome 3p by genetic linkage analysis.

Authors:  E R Maher; E Bentley; J R Yates; F Latif; M Lerman; B Zbar; N A Affara; M A Ferguson-Smith
Journal:  Genomics       Date:  1991-08       Impact factor: 5.736

3.  Diagnosis of genetic disease by primer-specified restriction map modification, with application to cystic fibrosis and retinitis pigmentosa.

Authors:  E J Sorscher; Z Huang
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

4.  Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of Von Hippel Lindau disease.

Authors:  B R Seizinger; D I Smith; M R Filling-Katz; H Neumann; J S Green; P L Choyke; K M Anderson; R N Freiman; S M Klauck; J Whaley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

5.  Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3.

Authors:  S Hosoe; H Brauch; F Latif; G Glenn; L Daniel; S Bale; P Choyke; M Gorin; E Oldfield; A Berman
Journal:  Genomics       Date:  1990-12       Impact factor: 5.736

6.  Screening for von Hippel-Lindau disease by DNA polymorphism analysis.

Authors:  G M Glenn; W M Linehan; S Hosoe; F Latif; M Yao; P Choyke; M B Gorin; E Chew; E Olfield; C Manolatos
Journal:  JAMA       Date:  1992-03-04       Impact factor: 56.272

7.  Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype.

Authors:  F Chen; T Kishida; M Yao; T Hustad; D Glavac; M Dean; J R Gnarra; M L Orcutt; F M Duh; G Glenn
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

8.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype.

Authors:  P A Crossey; F M Richards; K Foster; J S Green; A Prowse; F Latif; M I Lerman; B Zbar; N A Affara; M A Ferguson-Smith
Journal:  Hum Mol Genet       Date:  1994-08       Impact factor: 6.150

9.  Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma.

Authors:  B R Seizinger; G A Rouleau; L J Ozelius; A H Lane; G E Farmer; J M Lamiell; J Haines; J W Yuen; D Collins; D Majoor-Krakauer
Journal:  Nature       Date:  1988-03-17       Impact factor: 49.962

Review 10.  von Hippel-Lindau disease affecting 43 members of a single kindred.

Authors:  J M Lamiell; F G Salazar; Y E Hsia
Journal:  Medicine (Baltimore)       Date:  1989-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.